[
  {
    "ts": "2025-10-03T22:13:11+00:00",
    "headline": "AbbVie trims annual profit forecast after expected $2.7 billion R&D hit",
    "summary": "(Reuters) -Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in",
    "url": "https://finance.yahoo.com/news/abbvie-trims-annual-profit-forecast-221311853.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "3ed16582-96e9-34bf-909e-8edf61258f05",
      "content": {
        "id": "3ed16582-96e9-34bf-909e-8edf61258f05",
        "contentType": "STORY",
        "title": "AbbVie trims annual profit forecast after expected $2.7 billion R&D hit",
        "description": "",
        "summary": "(Reuters) -Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in",
        "pubDate": "2025-10-03T22:13:11Z",
        "displayTime": "2025-10-03T22:13:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/1b9d570cfa80c65234835aa93b9de164",
          "originalWidth": 800,
          "originalHeight": 457,
          "caption": "Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/h10oa.ZnGnqN0aczSTX3IQ--~B/aD00NTc7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/1b9d570cfa80c65234835aa93b9de164.cf.webp",
              "width": 800,
              "height": 457,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YKnJC0UV9DpOuMSxyOD_5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/1b9d570cfa80c65234835aa93b9de164.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-trims-annual-profit-forecast-221311853.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-trims-annual-profit-forecast-221311853.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-03T20:55:00+00:00",
    "headline": "5 Large Cap Drug Stocks: Values or Traps?",
    "summary": "Some drug stocks are cheap but is it another fake out?",
    "url": "https://finance.yahoo.com/news/5-large-cap-drug-stocks-205500435.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2cf623d8-c4c8-389d-ac3e-c7e716aea7f4",
      "content": {
        "id": "2cf623d8-c4c8-389d-ac3e-c7e716aea7f4",
        "contentType": "STORY",
        "title": "5 Large Cap Drug Stocks: Values or Traps?",
        "description": "",
        "summary": "Some drug stocks are cheap but is it another fake out?",
        "pubDate": "2025-10-03T20:55:00Z",
        "displayTime": "2025-10-03T20:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/2866fb9ec2bc73fc116e751457a731f2",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/35QPWEy.62iv0e1OjDB6fw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2866fb9ec2bc73fc116e751457a731f2.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dJfsiMgZFUxRCqwEV9t4Vg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2866fb9ec2bc73fc116e751457a731f2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-large-cap-drug-stocks-205500435.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-large-cap-drug-stocks-205500435.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-03T20:16:14+00:00",
    "headline": "How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment",
    "summary": "As the former BeiGene gears up to battle AbbVie and J&J, shares of the new BeOne Medicines haven't been this high in four years.",
    "url": "https://www.investors.com/research/the-new-america/beone-medicines-beigene-cancer-treatment/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "671ffe15-7bc9-3b15-8eff-8855c10dc03d",
      "content": {
        "id": "671ffe15-7bc9-3b15-8eff-8855c10dc03d",
        "contentType": "STORY",
        "title": "How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment",
        "description": "",
        "summary": "As the former BeiGene gears up to battle AbbVie and J&J, shares of the new BeOne Medicines haven't been this high in four years.",
        "pubDate": "2025-10-03T20:16:14Z",
        "displayTime": "2025-10-03T20:16:14Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/671ffe15-7bc9-3b15-8eff-8855c10dc03d/how-beone-medicines-an-ibd.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/a0a0f1d315d9e520d19faefdd708f9f3",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4Fon_Md8GOxdZzLxIrvepw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/a0a0f1d315d9e520d19faefdd708f9f3.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1RfKmHKwPsHEDwu.QlauOg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/a0a0f1d315d9e520d19faefdd708f9f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/research/the-new-america/beone-medicines-beigene-cancer-treatment/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "BEIGF"
            },
            {
              "symbol": "ONC"
            },
            {
              "symbol": "AZN.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-03T13:59:00+00:00",
    "headline": "Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?",
    "summary": "Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.",
    "url": "https://finance.yahoo.com/news/pfe-stock-buy-14-rise-135900538.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d9bfd1c5-7da0-3060-9f85-4d7707608b8a",
      "content": {
        "id": "d9bfd1c5-7da0-3060-9f85-4d7707608b8a",
        "contentType": "STORY",
        "title": "Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?",
        "description": "",
        "summary": "Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.",
        "pubDate": "2025-10-03T13:59:00Z",
        "displayTime": "2025-10-03T13:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YqcOBKMNrThKvJSga1KIbw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Vj9Bix098SQE5mY9G0P2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfe-stock-buy-14-rise-135900538.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfe-stock-buy-14-rise-135900538.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-03T11:44:54+00:00",
    "headline": "Does AbbVie's (ABBV) Manufacturing Expansion Signal a Shift in Its Long-Term Growth Focus?",
    "summary": "AbbVie recently submitted a Biologics License Application to the FDA for its investigational cancer therapy pivekimab sunirine and announced a US$70 million expansion of its Bioresearch Center in Massachusetts to enhance biologics manufacturing for immunology and oncology medicines. These moves highlight AbbVie's ongoing focus on strengthening its oncology pipeline and scaling domestic production in response to growing demand and policy incentives for US-based pharmaceutical...",
    "url": "https://finance.yahoo.com/news/does-abbvies-abbv-manufacturing-expansion-114454039.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "31f892aa-e2ae-36c9-b35d-59ed094f485d",
      "content": {
        "id": "31f892aa-e2ae-36c9-b35d-59ed094f485d",
        "contentType": "STORY",
        "title": "Does AbbVie's (ABBV) Manufacturing Expansion Signal a Shift in Its Long-Term Growth Focus?",
        "description": "",
        "summary": "AbbVie recently submitted a Biologics License Application to the FDA for its investigational cancer therapy pivekimab sunirine and announced a US$70 million expansion of its Bioresearch Center in Massachusetts to enhance biologics manufacturing for immunology and oncology medicines. These moves highlight AbbVie's ongoing focus on strengthening its oncology pipeline and scaling domestic production in response to growing demand and policy incentives for US-based pharmaceutical...",
        "pubDate": "2025-10-03T11:44:54Z",
        "displayTime": "2025-10-03T11:44:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-abbvies-abbv-manufacturing-expansion-114454039.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-abbvies-abbv-manufacturing-expansion-114454039.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-03T10:27:55+00:00",
    "headline": "Bernstein Remains a Hold on AbbVie Inc. (ABBV)",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best medical stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on AbbVie Inc. (NYSE:ABBV) without assigning a price target. AbbVie Inc. (NYSE:ABBV) reported in its fiscal Q2 2025 earnings that the diluted EPS for the quarter reached […]",
    "url": "https://finance.yahoo.com/news/bernstein-remains-hold-abbvie-inc-102755355.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "5149caf7-58f7-3b13-98cd-1506f3609da1",
      "content": {
        "id": "5149caf7-58f7-3b13-98cd-1506f3609da1",
        "contentType": "STORY",
        "title": "Bernstein Remains a Hold on AbbVie Inc. (ABBV)",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best medical stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on AbbVie Inc. (NYSE:ABBV) without assigning a price target. AbbVie Inc. (NYSE:ABBV) reported in its fiscal Q2 2025 earnings that the diluted EPS for the quarter reached […]",
        "pubDate": "2025-10-03T10:27:55Z",
        "displayTime": "2025-10-03T10:27:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Dividend Paying Stocks With Stability: AbbVie’s (ABBV) Consistent Record",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aXAa28AvezyRv056g_RUEg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lzVMSqWRbEKelBHS4c050A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bernstein-remains-hold-abbvie-inc-102755355.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bernstein-remains-hold-abbvie-inc-102755355.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-03T09:33:14+00:00",
    "headline": "Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the most undervalued stocks to buy and hold for 5 years. On October 1, Bristol-Myers Squibb, Takeda Pharmaceuticals (NYSE:TAK), and Astex Pharmaceuticals agreed to collaborate and pool proprietary data for drug discovery using an AI model. These companies are joining an existing consortium that already includes AbbVie Inc. […]",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-takeda-astex-093314157.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "20e08fe3-4668-3585-abca-0839d6d2b497",
      "content": {
        "id": "20e08fe3-4668-3585-abca-0839d6d2b497",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the most undervalued stocks to buy and hold for 5 years. On October 1, Bristol-Myers Squibb, Takeda Pharmaceuticals (NYSE:TAK), and Astex Pharmaceuticals agreed to collaborate and pool proprietary data for drug discovery using an AI model. These companies are joining an existing consortium that already includes AbbVie Inc. […]",
        "pubDate": "2025-10-03T09:33:14Z",
        "displayTime": "2025-10-03T09:33:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-takeda-astex-093314157.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-takeda-astex-093314157.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "4502.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-03T04:38:18+00:00",
    "headline": "2 Healthcare Stocks to Research Further and 1 Facing Challenges",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 6.5% has lagged the S&P 500’s 24.7% climb.",
    "url": "https://finance.yahoo.com/news/2-healthcare-stocks-research-further-043818122.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "45c50beb-d91d-3572-b24d-43e4b62cef5f",
      "content": {
        "id": "45c50beb-d91d-3572-b24d-43e4b62cef5f",
        "contentType": "STORY",
        "title": "2 Healthcare Stocks to Research Further and 1 Facing Challenges",
        "description": "",
        "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 6.5% has lagged the S&P 500’s 24.7% climb.",
        "pubDate": "2025-10-03T04:38:18Z",
        "displayTime": "2025-10-03T04:38:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "ABBV Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K222hrzb0FJJlqrDZzsz7w--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cD3IChyAhZhexmnMXW7jMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-healthcare-stocks-research-further-043818122.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-healthcare-stocks-research-further-043818122.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "UNH"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "IRTC"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]